Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (Nasdaq: ABCL) has expanded its intellectual property portfolio with the issuance of patent no. 10,881,084 for its Trianni Mouse® technology, aimed at enhancing antibody discovery. This technology allows the generation of fully human monoclonal antibodies, significantly increasing the speed and efficiency of therapeutic antibody development with partners. Carl Hansen, CEO, emphasized the patent's importance for protecting their proprietary technology in the U.S. The Trianni Mouse® platform is a key asset for developing advanced transgenic mouse technologies.
AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555), developed with Eli Lilly, will undergo a new pragmatic study targeting high-risk COVID-19 patients. This collaboration, with support from New Mexico, aims to evaluate bamlanivimab's effectiveness and safety in diverse environments. The antibody, authorized in the U.S. and Canada, has demonstrated success in reducing viral load and hospitalizations in previous studies. This initiative aligns with AbCellera's efforts in pandemic response, showcasing its capabilities developed over two years under DARPA's program.
AbCellera Biologics (Nasdaq: ABCL) has successfully closed its initial public offering of 27,772,500 common shares at $20.00 each, raising approximately $555.5 million before expenses. This includes the full exercise of underwriters' options for 3,622,500 additional shares. Following the IPO, convertible promissory notes worth around $90.0 million converted into 6,093,524 common shares at $17.00 per share. Credit Suisse and several other banks served as joint book-running managers for this offering.
AbCellera Biologics has priced its initial public offering (IPO) at $20.00 per share, offering 24,150,000 common shares, expected to yield gross proceeds of $483 million. The IPO is set to trade on Nasdaq under the ticker 'ABCL' starting December 11, 2020, with an anticipated closing date of December 15, 2020. Should underwriters exercise their option, an additional 3,622,500 shares may be purchased. Concurrently, $90 million in convertible notes issued previously will convert at $17.00 per share, reflecting a discount to IPO price.